A review of nutrients and botanicals in the integrative management of cognitive dysfunction

Alternative Medicine Review

Volumn 4, Issue 3, 1999, Pages 144-161

  Kidd, Parris M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GINKGO BILOBA EXTRACT; LEVACECARNINE; PHOSPHATIDYLSERINE; UNCLASSIFIED DRUG; VINPOCETINE;

BACOPA; COGNITIVE DEFECT; DIET THERAPY; DRUG EFFECT; HUMAN; MEMORY; REVIEW; TREATMENT OUTCOME;

ACETYLCARNITINE; COGNITION DISORDERS; COMPLEMENTARY THERAPIES; DEMENTIA; GINKGO BILOBA; HUMANS; NOOTROPIC AGENTS; PHOSPHATIDYLSERINES; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; RISK FACTORS; VINCA ALKALOIDS;

EID: 0033015960     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Crook TH, Adderly B. The Memory Cure. New York, NY: Simon and Shuster; 1998.
2. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
3. Crook TH. Treatment of age-related cognitive decline: effects of phosphatidylserine. In: Klatz R, Goldman R, eds. Anti-Aging Medical Therapeutics, Vol II. Marina Del Ray, CA: Healthquest; 1998:20-29.
4. Finch CE. Longevity, Senescence, and the Genome. Chicago, IL: The University Press; 1990.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 1994.
6. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease: The Nun Study. JAMA 1997;277:813-817.
7. Crook TH, Tinklenberg J, Yesavage J, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology 1991;41:644-649.
8. Small GW, Leiter F. Neuroimaging for diagnosis of dementia. J Clin Psychiatry 1998;59:4-7.
9. Small GW, La Rue A, Komo S, et al. Predictors of cognitive change in middle-aged and older adults with memory loss. Am J Psychiatry 1995;152:1757-1764.
10. Crawford JG. Alzheimer's disease risk factors as related to cerebral blood flow: additional evidence. Med Hypotheses 1998;50:25-36.
11. Frishman WH, Sokol S, Aronson MK, et al. Risk factors for cardiovascular and cerebrovascular diseases and dementia in the elderly. Curr Probl Cardiol 1998;23:1-62.
12. Itzhaki RF, Lin WR, Shang D, et al. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet 1997;349:241-244.
13. Riggs KM, Spiro A, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the normative aging study. Am J Clin Nutr 1996;63:306-314.
14. Skogh M. Extracts of Ginkgo biloba and bleeding or haemorrhage. Lancet 1998;352:1145-1146.
15. Small GW. The pathogenesis of Alzheimer's disease. J Clin Psychiatry 1998;59:7-14.
16. Sobel E, Dunn M, Davanipour Z, et al. Elevated risk of Alzheimer's disease among workers with likely electromagnetic field exposure. Neurology 1996;47:1477-1481.
17. Tang M, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-432.
18. White L, Petrovitch H, Ross GW, et al. Prevalence of dementia in older Japanese-American men in Hawaii. JAMA 1996;276:955-960.
19. Kidd PM. Liver biotransformation of xenobiotic chemicals, foods, and drugs to free radical oxidants. In: Levine SA, Kidd PM, ed. Antioxidant Adaptation: Its Role in Free Radical Pathology. San Leandro, CA: Allergy Research Group; 1985:221-281.
20. Mitchell J. Nowhere to hide: the global spread of high-risk synthetic chemicals. World Watch 1997;10:26-36.
21. Raloff J. Picturing pesticides' impacts on kids. Science News 1998;153:5.
22. Wolfe SM. Worst Pills, Best Pills II. Washington, DC: Public Citizen Health Research Group; 1993.
23. Lupien S, de Leon M, de Santi S, et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci 1998;1:69-73.
24. Geula C, Mesúlam M. Cortical cholinergic fibers in aging and Alzheimer's: a morphometric study. Neuroscience 1989;33:469-481.
25. West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal aging and Alzheimer's disease. Lancet 1994;344:769-772.
26. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-414.
27. Ahlin A, Nyback H, Junthe T,et al. Tetrahydroaminoacridine (THA) in Alzheimer's dementia: clinical and biochemical results of a double-blind cross over trial. Neurobiology of Aging 1990;11:344-350.
28. Knapp MJ, Knopmah DS, Solomon PR, et al. A 30 week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
29. Barner EL and Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1998;32:70-77.
30. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
31. Kidd PM. Phosphatidylserine, Number One Brain Booster. New Canaan, CT: Keats Publishing; 1998.
32. Burke ER, Fahey TD. PhosphatidylSerine: Promise for Athletic Performance. New Canaan, CT: Keats Publishing; 1998.
33. Cenacchi T, Bertoldin T, Farina C, et al. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milano) 1993;5:123-133.
34. Monteleone P, Beinat L, Tanzillo C, et al. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology 1990;52:243-248.
35. Monteleone P, Maj M, Beinat L, et al. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol 1992;42:385-388.
36. Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull 1992;28:61-66.
37. Amaducci L. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Psychopharmacol Bull 1988;24:130-134.
38. Villardita C, Grioli S, Salmeri G, et al. Multicentre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clin Trials J 1987;24:84-93.
39. Palmieri G, Palmieri R, Inzoli MR, et al. Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clin Trials J 1987;24:73-83.
40. Hershkowitz M, Fisher M, Bobrov D, et al. Long-term treatment of dementia Alzheimer type with Phosphatidylserine: effect on cognitive functioning and performance in daily life. In: Bazan NG, Horrocks LA, Toffano G, eds. Phospholipids in the Nervous System: Biochemical and Molecular Pathology. Padova, Italy: Liviana Press; 1989:279-288.
41. Funfgeld EW, Baggen M, Nedwidek P, et al. Double-blind study with phosphatidylserine (PS) in Parkinsonian patients with senile dementia of Alzheimer's type (SDAT) Prog Clin Biol Res 1989;317:1235-1246.
42. Delwaide PJ, Gyselynck-Mambourg AM, Hurlet A, Ylieff M. Double-blind randomized controlled study of phosphatidylserine in demented patients. Acta Neurol Scand 1986;73:136-140.
43. Maggioni M, Picotti GB, Bondiolotti GP, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand 1990;81:265-270.
44. Nerozzi D, Magnani A, Sforza V, et al. Early cortisol escape phenomenon reversed by phosphatidylserine in elderly normal subjects. Clinical Trials J 1989;26:33-38.
45. Masturzo P, Muriaido G, de Palma D, et al. TSH circadian secretions in aged men and effect of phosphatidylserine treatment. Chronobiologia 1990;17:267-274.
46. Kunin R, Kidd P. Pilot study of phosphatidylserine (PS) in young children with attentional and behavioral abnormalities. Unpublished;1998.
47. Kidd P, Ryser C. Benefits of phosphatidylserine (PS) on attention, learning, and mood in children and teenagers - a preliminary trial. Unpublished; 1999.
48. Fahey T, Pearl M. The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining. Biology Sport 1998;15:135-144.
49. Gindin J, Novikov M, Kedar D, et al. The effect of plant phosphatidylserine on age-associated memory impairment and mood in the functioning elderly. Rehovot, Israel: Geriatric Institute for Education and Research, and Department of Geriatrics, Kaplan Hospital;1995.
50. Toffano G, Battistella A, Orlando P, et al. Pharmacokinetics of radiolabelled brain phosphatidylserine. Clinical Trials J 1987;24:18-24.
51. Toffano G. The therapeutic value of phosphatidylserine effect in the aging brain. In: Hanin I, Ansell G, eds. Lecithin: Technological, Biological and Therapeutic Aspects. New York, NY: Plenum Press; 1987.
52. Kidd PM. Phosphatidylserine (PS), A Remarkable Brain Cell Nutrient. Decatur, IL: Lucas Meyer, Inc.; 1998.
53. Nunzi MG, Milan F, Guidolin D, Toffano G. Dendritic spine loss in hippocampus of aged rats Effect of brain phosphatidylserine administration. Neurobiol Aging 1987;8:501-510.
54. Klinkhammer P, Szelies B, Heiss W. Effect of phosphatidylserine on cerebral glucose metabolism in Alzheimer's Disease. Dementia 1990;1:197-201.
55. Angelucci L, Ramacci MT, Taglialatela G, et al. Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J Neuroscience Res 1988;20:491-496.
56. Crayhon R. The Carnitine Miracle. New York, NY: M. Evans and Co; 1998.
57. Livingston GA, Sax KB, McClenahan Z, et al. Acetyl-L-carnitine in dementia. International J Geriatr Psychiatr 1991;6:853-860.
58. Rai G, Wright G, Scott L, et al. Double-blind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin 1990;11:638-647.
59. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-1-carnitine treatment in Alzheimer's disease. Neurology 1991;41:1726-1732.
60. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's Disease. Arch Neurol 1992;49:1137-1141.
61. Thai LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996;47:705-711.
62. Brooks JO 3rd, Yesavage JA, Carta A, Bravi D. Acetyl-l-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int Psychogeriatr 1998;10:193-203.
63. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983;19:448-450.
64. Tempesta E, Troncon R, Janiri L, et al. Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism. Int J Clin Pharmacol Res 1990;10:101-107.
65. Bonavita E. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. Int J Clin Pharmacol Ther Toxicol 1986;24:511-516.
66. Pettegrew JW, Klunk WE, Panchalingam K, et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 1995;16:1-4.
67. Patti F. Effects of L-acetylcarnitine on functional recovery of hemiplegic patients. Clinical Trials J 1988;25:87-101.
68. Rampello L, Giammona G, Aleppo G, et al. Trophic action of acetyl-1-carnitine in neuronal cultures. Acta Neurol (Napoli) 1992;14:15-21.
69. Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of Vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc 1987;35:425-430.
70. Hindmarch I, Fuchs H, Erzigkeit H. Efficacy and tolerance of Vinpocetine in arrtbulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 1991;6:31-43.
71. Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology (Berl) 1990;101:147-159.
72. Thai LJ, Salmon DP, Lasker B, et al. The safety and lack of efficacy of Vinpocetine in Alzheimer's disease. J Am Geriatr Soc 1989;37:515-520.
73. Otomo E, Atarashi J, Araki G, et al. Comparison of Vinpocetine with ifenprodil tartrate and dihydroergotoxine mesylate treatment and results of long-term treatment with Vinpocetine. Curr Therapeutic Res 1985;37:811-821.
74. Tohgi H, Sasaki K, Chiba K, Nozaki Y. Effect of Vinpocetine on oxygen release of hemoglobin and erythrpcyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneim Forsch 1990;40:640-643.
75. Tamaki N, Kusunoki T, Matsumoto S. The effect of Vinpocetine on cerebral blood flow in patients with cerebrovascular disorders. Ther Hung 1985;33:13-21.
76. Osawa M, Maruyama S. Effects of TCV-3B (Vinpocetine) on blood viscosity in ischemic cerebrovascular diseases. Ther Hung 1985;33:7-12.
77. Hayakawa M. Comparative efficacy of Vinpocetine, pentoxifylline and nicergoline on red blood cell deformability. Arzneimittelforschung 1992;42:108-110.
78. Hayakawa, M. Effect of Vinpocetine on red blood cell deformability in stroke patients. Arzneimittelforschung 1992;42:425-427.
79. Bayer R, Plewa S, Borcescu E, Claus W. Filterability of human erythrocytes - drug induced prevention of aging in vitro. Arzneimittelforschung 1988;38:1765-1767.
80. Kuzuya F. Effects of Vinpocetine on platelet aggregability and erythrocyte deformability. Ther Hung 1985;33:22-34.
81. Olah VA, Balla G, Balla J, et al. An in vitro study of the hydroxyl scavenger effect of cavinton. Acta Paediatr Hung 1990;30:309-316.
82. Ueyoshi A, Ota K. Clinical appraisal of Vinpocetine for the removal of intractable tumoral calcinosis in haemodialysis patients with renal failure. J Int Med Res 1992;20:435-443.
83. Ribari O, Zelen B, Kollar B. Ethyl apovincaminate in the treatment of sensorineural impairment of hearing. Arzneimittelforschung 1976;26:1977-1980.
84. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992;34:352-358.
85. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer Disease. Arch Neurology 1998;55:1409-1415.
86. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb study group. JAMA 1997;278:1327-1332.
87. Itil T, Martorano D. Natural substances in psychiatry (Ginkgo biloba in dementia). Psychopharmacol Bull 1995;31:147-158.
88. Itil TM, Erlap E, Ahmed I, et al. The pharmacological effects of Ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacol Bull 1998;34:391-397.
89. Corrigan M. Personal communication; 1999 Springville, UT: Murdock Madaus Schwabe Co.
90. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998;352:36.
91. Odawara M, Tamaoka A, Yamashita K. Ginkgo biloba. Neurology 1997;48:789-790. [Letter]
92. Gilbert GJ. Ginkgo biloba. Neurology 1997;48:1137. [Letter]
93. Badmaev V. Bacopin (Bacopa monniera): A Memory Enhancer from Ayurveda. Piscataway, NJ: Sabinsa Corporation; 1998.
94. Singh HK, Dhawan BN. Effect of Bacopa monniera linn (Brahmi) extract on avoidance responses in rat. J Ethnopharmacol 1982;5:205-214.
95. Singh RH, Singh L. Studies on the anti-anxiety effect of the medyha rasayana drug, Brahmi (Bacopa monniera Wettst.)-part1. J Res Ayur Siddha 1980;1:133-148.
96. Sharma R, Chaturvedi C, Tewari PV. Efficacy of Bacopa monniera in revitalizing intellectual functions in children. J Res Edu Ind Med 1987:1-12.
97. Khalsa DS. Brain Longevity: How to Regenerate Your Mind for Peak Mental Performance. New York, NY: Warner Books; 1997.
98. Nudo RJ, Wise BM, SiFuentes F, Milliken GW. Neural substrates for the effects of rehabilitative training on motor recovery after ischemic infarct. Science 1996;272:1791-1794.
99. Neubauer RA, Gottlieb SF, Kagan RL. Enhancing "idling" neurons. Lancet 1990;335:542.
100. Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998;4:1313-1317.
101. Finkel E. Stem cells in brain have regenerative potential. Lancet 1996;347:751.
102. Kempermann G, Gage FH. New nerve cells for the adult brain. Sci Am 1999;280:48-53.
103. Gould E, Beylin A, Tanapat P, et al. Learning enhances adult neurogenesis in the hippocampal formation. Nat Neurosci 1999;2:260-265.